Medical Xpress August 2, 2024
A drug that was developed to treat pancreatic cancer has now been shown to increase symptom-free survival in preclinical medulloblastoma models—all without showing signs of toxicity.
Medulloblastoma is the most common malignant brain tumor in children. Survival rates vary according to which one of the four subtypes a patient has, but the worst survival rates, historically at about 40%, are for Group 3, which this research focused on.
Jezabel Rodriguez Blanco, Ph.D., an assistant professor who holds dual appointments at MUSC Hollings Cancer Center and the Darby Children’s Research Institute at MUSC, led the research, published in the Journal of Clinical Investigation.
Her research focused on the drug triptolide, which is extracted from a vine used in traditional Chinese medicine,...
Today's Sponsors
Today's Sponsor